Status:

RECRUITING

Safety, Tolerability and Pharmacokinetics of Lumateperone in Pediatric Patients With Autism Spectrum Disorder

Lead Sponsor:

Intra-Cellular Therapies, Inc.

Conditions:

Autism Spectrum Disorder

Eligibility:

All Genders

5-12 years

Phase:

PHASE1

Brief Summary

Study ITI-007-035 is a Phase 1b, multicenter, open-label study to evaluate the safety, tolerability, and PK of lumateperone for pediatric patients with Autism Spectrum Disorder.

Eligibility Criteria

Inclusion

  • Male or female patients between 5 to less than 13 years of age
  • Primary clinical diagnosis of ASD with symptoms of irritability
  • ABC-I subscale score of ≥12 at Screening
  • CGI-S score of ≥3 at Screening
  • Body mass index (BMI) greater than the 5th percentile according to age- and gender-specific CDC Clinical Growth Charts (2000) at Screening
  • Ability to swallow capsules

Exclusion

  • Has a primary psychiatric diagnosis other than ASD
  • Reports suicidal ideation (Type 3, 4 or 5 on the Baseline/Screening version of the C-SSRS) within 6 months prior to Screening, or any suicidal behavior within 2 years prior to Screening, and/or the Investigator assesses the patient to be a safety risk to him/herself or others
  • Clinically significant abnormality within 2 years of Screening that in the Investigator's opinion may place the patient at risk or interfere with study outcome variables
  • History of a clinically significant cardiac disorder and/or abnormal screening ECG or a QT interval corrected for heart rate using Fridericia formula (QTcF) \> 460 msec at Screening
  • Patients with a history of orthostatic hypotension or who have orthostatic hypotension at Screening
  • Has a history of uncontrolled/disruptive behavior in the past 30 days that, in the Investigator's opinion, would preclude the ability to participate in study procedures

Key Trial Info

Start Date :

May 10 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 31 2026

Estimated Enrollment :

26 Patients enrolled

Trial Details

Trial ID

NCT06557902

Start Date

May 10 2024

End Date

July 31 2026

Last Update

August 16 2024

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

Clinical Site 6

Miami, Florida, United States, 33133

2

Clinical Site 7

Orlando, Florida, United States, 32803

3

Clinical Site 1

Atlanta, Georgia, United States, 30331

4

Clinical Site 2

Decatur, Georgia, United States, 30030